🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 13 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 11/11/2015 | 119,59 | 119,90 | 117,52 | 118,20 | -0,59% | 1,99% | 1.052.300 |
| 10/11/2015 | 118,80 | 119,95 | 117,56 | 118,90 | +0,04% | 2,01% | 1.034.600 |
| 09/11/2015 | 117,70 | 120,11 | 116,94 | 118,85 | +0,75% | 2,69% | 1.521.300 |
| 06/11/2015 | 120,25 | 121,34 | 117,01 | 117,96 | -3,24% | 3,60% | 2.526.400 |
| 05/11/2015 | 125,00 | 126,34 | 121,82 | 121,91 | -2,39% | 3,62% | 1.485.300 |
| 04/11/2015 | 128,88 | 128,94 | 122,56 | 124,90 | -2,70% | 4,95% | 1.614.400 |
| 03/11/2015 | 127,21 | 128,98 | 125,62 | 128,36 | +1,12% | 2,64% | 1.811.900 |
| 02/11/2015 | 123,60 | 128,35 | 122,71 | 126,94 | +1,76% | 4,56% | 1.854.700 |
| 30/10/2015 | 126,93 | 126,93 | 122,69 | 124,74 | -1,13% | 3,34% | 2.033.500 |
| 29/10/2015 | 126,56 | 129,13 | 122,68 | 126,17 | +5,05% | 5,10% | 3.563.000 |
| 28/10/2015 | 120,40 | 121,87 | 116,52 | 120,10 | -0,75% | 4,44% | 3.676.500 |
| 27/10/2015 | 114,84 | 121,11 | 113,50 | 121,01 | +5,44% | 6,63% | 2.430.900 |
| 26/10/2015 | 114,29 | 117,28 | 112,11 | 114,77 | +0,35% | 4,52% | 1.518.600 |
| 23/10/2015 | 110,81 | 114,55 | 110,08 | 114,37 | +4,46% | 4,03% | 1.656.800 |
| 22/10/2015 | 109,87 | 111,29 | 107,46 | 109,49 | -0,12% | 3,49% | 1.844.700 |
| 21/10/2015 | 112,01 | 112,41 | 106,30 | 109,62 | -0,57% | 5,45% | 1.624.500 |
| 20/10/2015 | 115,71 | 115,87 | 110,07 | 110,25 | -4,86% | 5,01% | 1.683.700 |
| 19/10/2015 | 113,43 | 117,58 | 112,76 | 115,88 | +1,36% | 4,25% | 1.894.500 |
| 16/10/2015 | 116,04 | 118,83 | 112,50 | 114,32 | -1,27% | 5,46% | 1.936.500 |
| 15/10/2015 | 113,07 | 115,88 | 111,47 | 115,79 | +2,20% | 3,90% | 2.010.300 |
| 14/10/2015 | 109,81 | 114,95 | 109,63 | 113,30 | +3,56% | 4,84% | 2.336.000 |
| 13/10/2015 | 112,51 | 114,56 | 109,17 | 109,40 | -3,40% | 4,79% | 1.676.200 |
| 12/10/2015 | 110,64 | 114,25 | 109,08 | 113,25 | +2,95% | 4,67% | 1.860.800 |
| 09/10/2015 | 109,42 | 112,50 | 107,72 | 110,00 | +0,89% | 4,37% | 1.861.400 |
| 08/10/2015 | 109,25 | 110,50 | 102,96 | 109,03 | -0,34% | 6,90% | 2.745.700 |
| 07/10/2015 | 110,54 | 112,48 | 106,52 | 109,40 | -0,05% | 5,39% | 2.662.000 |
| 06/10/2015 | 113,55 | 114,50 | 104,17 | 109,46 | -4,42% | 9,10% | 3.566.600 |
| 05/10/2015 | 116,76 | 117,21 | 112,52 | 114,52 | -0,57% | 4,02% | 2.344.400 |
| 02/10/2015 | 107,24 | 115,23 | 106,01 | 115,18 | +7,41% | 8,60% | 3.527.700 |
| 01/10/2015 | 103,20 | 107,43 | 101,49 | 107,23 | +2,97% | 5,76% | 2.487.200 |